Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT
27 ledna, 2021 8:38 pmAuthor(s): Carolina Lazzarino, Marcelo Iastrebner, Jacqueline Gonzalez, Jorge Arbelbide, et al. Abstract: PS1259 Session topic: 10. Myelodysplastic syndromes...
MYELODYSPLASTICKÝ SYNDROM – VÝBĚR Z EDUKAČNÍCH SDĚLENÍ A POSTERŮ
27 ledna, 2021 8:38 pmPráce publikované formou edukačních sdělení 1. FACING THE CHALLENGE: NOVEL TREATMENT OPTIONS FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES Nové léčebné...
AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES BY PRIOR LINES OF THERAPY IN ZUMA-1
27 ledna, 2021 8:38 pmAuthor(s): Frederick L. Locke, Armin Ghobadi, Lazaros J. Lekakis, et. al. Abstract: S801 Session topic: 21. Aggressive Non-Hodgkin...
AN UPDATED ANALYSIS OF JULIET, A GLOBAL PIVOTAL PHASE 2 TRIAL OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
27 ledna, 2021 8:38 pmAuthor(s): Peter Borchmann, Constantine S. Tam, Ulrich Jäger Abstract: S799 Session topic: 21. Aggressive Non-Hodgkin lymphoma – Clinical...
RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
27 ledna, 2021 8:38 pmAuthor(s): Frank Morschhauser, Nathan H. Fowler, Pierre Feugier, et. al Abstract: S154 Session topic: 20. Indolent Non-Hodgkin lymphoma...
ADDING POLATUZUMAB VEDOTIN (POLA) TO BENDAMUSTINE AND RITUXIMAB (BR) TREATMENT IMPROVES SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: RESULTS OF A PHASE 2 CLINICAL TRIAL
27 ledna, 2021 8:38 pmAuthor(s): Laurie H. Sehn, Manali Kamdar, Alex F. Herrera, et. al. Abstract: S802 Session topic: 21. Aggressive Non-Hodgkin...
FINAL ANALYSIS OF THE AHL201 RANDOMIZED PHASE III LYSA STUDY COMPARING AN EARLY PET DRIVEN TREATMENT DE-ESCALATION TO A NOT PET-MONITORED STRATEGY IN PATIENTS WITH ADVANCED STAGES HODGKIN LYMPHOMA
27 ledna, 2021 8:38 pmAuthor(s): Olivier Casasnovas, Pauline Brice, Reda Bouabdallah, et. al Abstract: S110 Session topic: 17. Hodgkin lymphoma – Clinical...
PRETREATMENT VITAMIN D DEFICIENCY IS ASSOCIATED WITH LOWER PROGRESSION- -FREE AND OVERALL SURVIVAL IN PROSPECTIVELY TREATED HODGKIN LYMPHOMA
27 ledna, 2021 8:38 pmAuthor(s): Sven Borchmann, Helen Görgen, Stephanie Sasse, et. al. Abstract: S111 Session topic: 17. Hodgkin lymphoma – Clinical...
Nedostatok vitamínu D a znížené prežívanie pacientov s Hodgkinovým lymfómom
27 ledna, 2021 8:38 pmAutori tejto práce testovali hypotézu, či znížená hladina vitamínu D znižuje prežívanie bez progresie (PFS) a celkové prežívanie (OS) pacientov s Hodgkinovým...
RESULTS FROM 48-WEEK FOLLOW-UP OF THE EXPAND STUDY: A PHASE 1B, OPEN-LABEL, DOSE-FINDING STUDY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND LOW PLATELET COUNTS (50-99 × 109/L) AT BASELINE
27 ledna, 2021 8:37 pmAuthor(s): Alessandro M. Vannucchi, Peter te Boekhorst, Claire N. Harrison, Guangsheng He, Marianna Caramella, Dietger Niederwieser, Françoise Boyer-Perrard, Minghui Duan,...